Alzheimer’s drug lecanemab hailed as momentous breakthrough
Lecanemab is the first drug to remove damage, but there are questions around its impact, side effects and use. …
One of the world’s leading researchers behind the whole idea of targeting amyloid 30 years ago, Prof John Hardy, said it was “historic” and was optimistic “we’re seeing the beginning of Alzheimer’s therapies”. Prof Tara Spires-Jones, from the University of Edinburgh, said the results were “a big deal because we’ve had a 100% failure rate for a long time”.
About The Author
